NextCure, Inc.
For the period ended Jun 18, 2026. Filed Jun 25, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 18, 2026 · Filed Jun 25, 2026
Use the contents to explore the available documents and sections.
Contents
PROXY STATEMENT
proxy statement on Schedule 14A which was filed with the Securities and Exchange Commission on April 24, 2026. The above summary of the A&R 2019 Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the A&R 2019 Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.
On June 18, 2026, the Company held its Annual Meeting. At the Annual Meeting, the Company’s stockholders: (i) elected two Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; (iii) approved, on an advisory basis, the compensation paid to the Company’s named executive officers; and (iv) approved the A&R 2019 Plan to, among other items, increase the number of shares of common stock authorized for issuance thereunder. The results of the voting at the Annual Meeting are shown below.
Proposal No. 1: Election of Class I Directors
| · · · | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nominee | | For | | Against | | Abstain | | Broker Non-Votes |
| Anne Borgman, M.D. | | 1,595,507 | | 522,009 | | 139 | | 698,319 |
| John G. Houston, PH.D. | | 1,961,916 | | 155,737 | | 2 | | 698,319 |
*Proposal No. 2:
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.